PT3478286T - Métodos de tratamento do cancro do ovário - Google Patents
Métodos de tratamento do cancro do ovárioInfo
- Publication number
- PT3478286T PT3478286T PT178212627T PT17821262T PT3478286T PT 3478286 T PT3478286 T PT 3478286T PT 178212627 T PT178212627 T PT 178212627T PT 17821262 T PT17821262 T PT 17821262T PT 3478286 T PT3478286 T PT 3478286T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- ovarian cancer
- treating ovarian
- treating
- cancer
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356461P | 2016-06-29 | 2016-06-29 | |
| US201662402427P | 2016-09-30 | 2016-09-30 | |
| US201762470141P | 2017-03-10 | 2017-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3478286T true PT3478286T (pt) | 2024-01-31 |
Family
ID=60787744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT178212627T PT3478286T (pt) | 2016-06-29 | 2017-06-29 | Métodos de tratamento do cancro do ovário |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US12383542B2 (enExample) |
| EP (2) | EP3478286B1 (enExample) |
| JP (2) | JP7083760B2 (enExample) |
| KR (2) | KR102510996B1 (enExample) |
| CN (1) | CN109640992A (enExample) |
| AU (1) | AU2017290244B2 (enExample) |
| BR (1) | BR112018077492A2 (enExample) |
| CA (1) | CA3029671C (enExample) |
| DK (1) | DK3478286T3 (enExample) |
| ES (1) | ES2969816T3 (enExample) |
| FI (1) | FI3478286T3 (enExample) |
| HR (1) | HRP20240136T1 (enExample) |
| HU (1) | HUE064978T2 (enExample) |
| IL (1) | IL263925B2 (enExample) |
| LT (1) | LT3478286T (enExample) |
| MX (1) | MX394062B (enExample) |
| NZ (1) | NZ749413A (enExample) |
| PL (1) | PL3478286T3 (enExample) |
| PT (1) | PT3478286T (enExample) |
| RS (1) | RS65180B1 (enExample) |
| SG (1) | SG11201811564QA (enExample) |
| SI (1) | SI3478286T1 (enExample) |
| SM (1) | SMT202400105T1 (enExample) |
| WO (1) | WO2018005818A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3478286B1 (en) | 2016-06-29 | 2024-01-03 | Tesaro, Inc. | Methods of treating ovarian cancer |
| EP3666794A1 (en) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| EP3689419A1 (en) | 2016-11-01 | 2020-08-05 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
| CN110382000A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗tim-3抗体治疗癌症的方法 |
| MX2019011496A (es) | 2017-03-27 | 2020-01-23 | Tesaro Inc | Composiciones de niraparib. |
| MA48475A (fr) | 2017-04-24 | 2020-03-04 | Tesaro Inc | Procédés de fabrication de niraparib |
| TWI879716B (zh) * | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| MA49144A (fr) | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| BR112020006039A2 (pt) | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
| CA3076515A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | Combination therapies for treating cancer |
| MA50618A (fr) | 2017-10-06 | 2020-08-12 | Tesaro Inc | Polyrhérapies et leurs utilisations |
| KR20200118117A (ko) * | 2018-02-05 | 2020-10-14 | 테사로, 인코포레이티드 | 소아용 니라파립 제제 및 소아용 치료 방법 |
| WO2019195443A1 (en) * | 2018-04-04 | 2019-10-10 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor |
| EP3860988A1 (en) | 2018-10-03 | 2021-08-11 | Tesaro, Inc. | Crystalline forms of niraparib freebase |
| ES2967517T3 (es) | 2018-10-03 | 2024-04-30 | Tesaro Inc | Sales de niraparib |
| US10395772B1 (en) | 2018-10-17 | 2019-08-27 | Tempus Labs | Mobile supplementation, extraction, and analysis of health records |
| EP3857555A4 (en) | 2018-10-17 | 2022-12-21 | Tempus Labs | DATA-BASED CANCER RESEARCH AND TREATMENT SYSTEMS AND PROCEDURES |
| CA3122070A1 (en) | 2018-12-03 | 2020-06-11 | Tempus Labs, Inc. | Clinical concept identification, extraction, and prediction system and related methods |
| JP2022516170A (ja) * | 2019-01-04 | 2022-02-24 | アクティニウム ファーマシューティカルズ インコーポレイテッド | Ｐａｒｐインヒビターおよび抗体放射性物質結合体の組み合わせを使用してがんを処置するための方法 |
| US11705226B2 (en) | 2019-09-19 | 2023-07-18 | Tempus Labs, Inc. | Data based cancer research and treatment systems and methods |
| TW202116316A (zh) * | 2019-07-15 | 2021-05-01 | 美商提薩羅有限公司 | 治療卵巢、輸卵管及腹膜癌之方法 |
| AU2020332939B2 (en) * | 2019-08-22 | 2025-12-11 | Tempus Ai, Inc. | Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data |
| EP4085053A4 (en) * | 2019-12-31 | 2023-12-27 | Kinnate Biopharma Inc. | TREATING CANCER WITH CDK12/13 INHIBITORS |
| EP4090380A1 (en) * | 2020-01-13 | 2022-11-23 | Gradalis, Inc. | Methods for treating cancers using gm-csf encoding polynucleotide and additional agents |
| CN116490776A (zh) * | 2020-10-29 | 2023-07-25 | 德州大学系统董事会 | 用于检测和治疗卵巢癌的方法 |
| KR102858757B1 (ko) | 2022-01-25 | 2025-09-10 | 서울대학교산학협력단 | 상동 재조합 결핍 연관 유전자 도출 장치 및 방법, 상동 재조합 결핍 판단 모델 생성 장치 및 방법과, 상동 재조합 결핍 판단 장치 및 방법 |
| CN119156216A (zh) | 2022-02-15 | 2024-12-17 | 特沙诺有限公司 | 尼拉帕尼用于治疗脑癌的用途 |
| CN115253066A (zh) * | 2022-07-21 | 2022-11-01 | 湖南安泰康成生物科技有限公司 | 卵巢癌治疗系统以及卵巢癌治疗的交变电场发生装置 |
| CN116092631A (zh) * | 2023-01-17 | 2023-05-09 | 湖南安泰康成生物科技有限公司 | 铁死亡诱导剂与电场联用的肿瘤治疗系统 |
| WO2025061057A1 (en) * | 2023-09-19 | 2025-03-27 | Impact Therapeutics (Shanghai) , Inc | Use of a parp inhibitor in maintenance therapy of ovarian cancer |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4611441B2 (ja) | 2006-04-03 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体 |
| GEP20115337B (en) | 2007-01-10 | 2011-11-25 | St Di Ricerche Di Biologia Molecolare P Angeletti Spa | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| KR101598231B1 (ko) | 2007-10-17 | 2016-02-26 | 쿠도스 파마슈티칼스 리미티드 | 4-[3-(4-시클로프로판카르보닐-피페라진-1-카르보닐)-4-플루오로-벤질]-2ｈ-프탈라진-1-온 |
| NZ586123A (en) * | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors |
| US8500933B2 (en) | 2007-12-14 | 2013-08-06 | Guardian Industries Corp. | Localized heating of edge seals for a vacuum insulating glass unit, and/or unitized oven for accomplishing the same |
| NZ586675A (en) | 2008-01-08 | 2012-04-27 | Merck Sharp & Dohme | Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| JP5468015B2 (ja) | 2008-01-08 | 2014-04-09 | アクセリア ファーマシューティカルズ | 抗菌ペプチド系に対する作動薬 |
| EA020756B1 (ru) | 2009-08-26 | 2015-01-30 | Сефалон, Инк. | Новые формы полициклического соединения |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| WO2011153383A1 (en) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
| WO2011160063A2 (en) | 2010-06-18 | 2011-12-22 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| CA2779052A1 (en) | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| WO2014052550A1 (en) * | 2012-09-27 | 2014-04-03 | Thomas Jefferson University | Use of parp inhibitors to treat breast cancer |
| US20150313922A1 (en) | 2012-11-28 | 2015-11-05 | Sloan-Kettering Institute For Cancer Research | Compositions and methods for the treatment of cancers associated with a deficiency in the mre11/rad50/nbs1 dna damage repair complex |
| EP3406594A1 (en) | 2012-12-07 | 2018-11-28 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| WO2014138101A1 (en) | 2013-03-04 | 2014-09-12 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (hr) deficient cancer |
| AU2014248007B2 (en) * | 2013-04-05 | 2020-03-26 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| CN105917007A (zh) | 2014-01-16 | 2016-08-31 | 克洛维斯肿瘤有限公司 | Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 |
| AU2015214390B2 (en) | 2014-02-04 | 2020-05-07 | Merck Sharp & Dohme LLC. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
| WO2015136017A1 (en) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| WO2015184145A1 (en) * | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| US20150344968A1 (en) * | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| CN105384695B (zh) * | 2014-08-22 | 2019-12-20 | 四川海思科制药有限公司 | 嘧啶衍生物及其制备方法和在医药上的应用 |
| CA2959072A1 (en) | 2014-08-25 | 2016-03-03 | Creatv Microtech, Inc. | Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them |
| US20160160294A1 (en) | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| WO2016200835A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| SI3317281T1 (sl) | 2015-07-02 | 2020-08-31 | Acerta Pharma B.V. | Trdne oblike in formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin -2-il)imidazo(1,5-a)pirazin-1-il)-n-(piridin-2-il)benzamida |
| CA3003422A1 (en) | 2015-10-26 | 2017-05-04 | Medivation Technologies Llc | Treatment of small cell lung cancer with a parp inhibitor |
| EP3414692A4 (en) | 2016-02-12 | 2020-07-29 | Nantomics, LLC | HIGH-RATE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES |
| CN108697666A (zh) * | 2016-02-29 | 2018-10-23 | 辛塔制药公司 | 用于治疗卵巢癌的组合疗法 |
| EP3478286B1 (en) | 2016-06-29 | 2024-01-03 | Tesaro, Inc. | Methods of treating ovarian cancer |
| WO2018023017A1 (en) | 2016-07-29 | 2018-02-01 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer |
| CN106496187A (zh) | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| CN106432055A (zh) | 2016-09-17 | 2017-02-22 | 青岛辰达生物科技有限公司 | 一种尼拉帕布中间体4‑（哌啶‑3‑基）苯胺的制备方法 |
| MX2019011496A (es) | 2017-03-27 | 2020-01-23 | Tesaro Inc | Composiciones de niraparib. |
| EP3606523A1 (en) | 2017-03-27 | 2020-02-12 | Tesaro, Inc. | Niraparib formulations |
| MA48475A (fr) | 2017-04-24 | 2020-03-04 | Tesaro Inc | Procédés de fabrication de niraparib |
| NZ759517A (en) | 2017-04-27 | 2025-02-28 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| US20200129482A1 (en) | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
| BR112020006039A2 (pt) | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| KR20200105862A (ko) | 2017-12-27 | 2020-09-09 | 테사로, 인코포레이티드 | 암을 치료하는 방법 |
| TW202116316A (zh) | 2019-07-15 | 2021-05-01 | 美商提薩羅有限公司 | 治療卵巢、輸卵管及腹膜癌之方法 |
-
2017
- 2017-06-29 EP EP17821262.7A patent/EP3478286B1/en active Active
- 2017-06-29 NZ NZ749413A patent/NZ749413A/en unknown
- 2017-06-29 MX MX2018016193A patent/MX394062B/es unknown
- 2017-06-29 KR KR1020197002633A patent/KR102510996B1/ko active Active
- 2017-06-29 PT PT178212627T patent/PT3478286T/pt unknown
- 2017-06-29 SG SG11201811564QA patent/SG11201811564QA/en unknown
- 2017-06-29 PL PL17821262.7T patent/PL3478286T3/pl unknown
- 2017-06-29 JP JP2018568951A patent/JP7083760B2/ja active Active
- 2017-06-29 RS RS20240163A patent/RS65180B1/sr unknown
- 2017-06-29 CN CN201780051916.1A patent/CN109640992A/zh active Pending
- 2017-06-29 SM SM20240105T patent/SMT202400105T1/it unknown
- 2017-06-29 FI FIEP17821262.7T patent/FI3478286T3/fi active
- 2017-06-29 SI SI201731481T patent/SI3478286T1/sl unknown
- 2017-06-29 CA CA3029671A patent/CA3029671C/en active Active
- 2017-06-29 ES ES17821262T patent/ES2969816T3/es active Active
- 2017-06-29 HR HRP20240136TT patent/HRP20240136T1/hr unknown
- 2017-06-29 HU HUE17821262A patent/HUE064978T2/hu unknown
- 2017-06-29 KR KR1020237008762A patent/KR20230042136A/ko not_active Ceased
- 2017-06-29 IL IL263925A patent/IL263925B2/en unknown
- 2017-06-29 AU AU2017290244A patent/AU2017290244B2/en active Active
- 2017-06-29 DK DK17821262.7T patent/DK3478286T3/da active
- 2017-06-29 BR BR112018077492-8A patent/BR112018077492A2/pt not_active Application Discontinuation
- 2017-06-29 EP EP23211450.4A patent/EP4302835A3/en active Pending
- 2017-06-29 LT LTEPPCT/US2017/040039T patent/LT3478286T/lt unknown
- 2017-06-29 WO PCT/US2017/040039 patent/WO2018005818A1/en not_active Ceased
-
2018
- 2018-05-22 US US15/986,536 patent/US12383542B2/en active Active
-
2021
- 2021-12-27 JP JP2021212103A patent/JP2022031478A/ja active Pending
-
2022
- 2022-02-24 US US17/652,443 patent/US20220175752A1/en not_active Abandoned
- 2022-02-24 US US17/652,422 patent/US20220175751A1/en not_active Abandoned
- 2022-02-24 US US17/652,457 patent/US20220395493A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/463,851 patent/US20240058319A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263925A (en) | Methods of treating ovarian cancer | |
| IL275663A (en) | Cancer treatment methods | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL255189A0 (en) | Cancer treatment methods | |
| SG10202110594UA (en) | Methods of treating tumor | |
| IL255569A (en) | Methods of treating cancer using anti-ox40 antibodies | |
| HUE052106T2 (hu) | Eljárás rák kezelésére | |
| IL262342A (en) | Cancer treatment methods | |
| ZA201808258B (en) | Methods of treating pancreatic cancer | |
| PT3490560T (pt) | Niraparib para utilização num método de tratamento de cancro da próstata | |
| IL261195B (en) | Combined treatment for ovarian cancer | |
| ZA201802481B (en) | Novel biomarkers and methods of treating cancer | |
| EP3119390A4 (en) | Methods of treating cancer | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| IL271934A (en) | Methods for treating tumor metastases | |
| EP3487999A4 (en) | METHODS OF TREATING CANCER | |
| SG11202005163PA (en) | Methods of treating cancer | |
| IL272379B2 (en) | Methods for treating cancer using SETDs inhibition | |
| IL269123A (en) | Methods of treating cancer | |
| EP3389670A4 (en) | METHODS OF TREATING BREAST CANCER | |
| IL265537A (en) | Methods of treating ovarian cancer | |
| GB201510197D0 (en) | Method of treating ovarian cancer | |
| HK40006340A (en) | Methods for treating ovarian cancer | |
| GB201622214D0 (en) | treatment of cancer | |
| GB201604621D0 (en) | Treatment of cancer |